Chest pain drug falls short in preventing first episode of ventricular arrhythmia or death


IMAGE: A trial of more than 1,000 patients with implantable cardioverter defibrillators found that the drug ranolazine was safe but didn't decrease the... view A clinical trial of more than 1,000 patients with implantable cardioverter defibrillators found that the drug ranolazine was safe but didn't significantly decrease the likelihood of the first occurrence of ventricular tachycardia, ventricular fibrillation or death in this high-risk population. The study was published recently in JACC , the Journal of the American College of Cardiology .



from Biotech News